Adma Biologics reported $75.76M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Adma Biologics USD 75.76M 2.22M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
BioCryst Pharmaceuticals USD 208.85M 13.46M Jun/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Novavax USD 330.57M 11.89M Jun/2026
Omeros USD 85.5M 2.28M Jun/2025
Takeda JPY 2.76T 335.02B Jun/2026